Метформин

Новоселов Валерий с профессором Коневым в 24 номере Клиническая геронтология УДК 612.67 DOI: 10.26347/1607-2499201801-02062-065

О ГЕРОПРОТЕКЦИИ И МЕТФОРМИНЕ

ON GEROPROTECTION AND METFORMIN

Increasingly important social and economic problem in all developed countries, where the number of elderly people is about 20–25% of the total population is a fast growth and steady aging of the population, and therefore in the interests of the state and of the elderly person is to stay healthy and capable of self-care as long as possible. In the media, we can see a lot of recommendations, «how to increase life expectancy», often from sources with no direct or indirect relationship to medicine. Moreover, it does matter when the so-called «gerontology-business» began to recommend the finished product with the aim of extending the human life with the sole purpose to create thereby a huge multibillion-dollar business in the human desire to live for a long time. Metformin is one of such drugs, although according to the manufacturers’ recommendations, these drugs do not have even minimal references to geroprotection. Over 60 years of use of Metformin, reliable data on the possible extension of human life has not been received. The proposal from biologists to recognize the Metformin hydrochloride and a variety of other drugs geroprotectors without longitudinal clinical trials on humans will do more harm than good for the people of the «third age» who are unable to resist such aggressive advertising and similar methods of promotion of drugs. Key words: geroprotection, Metformin, use such drugs as geroprotectors.

Authors declare lack of the possible conflicts of interests